Sign In
Buy NRSN
$0.465
-0.0108 (-2.27%)
At Close: Jul 31, 2026
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower func
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
11:07am, Monday, 09'th Mar 2026
CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 14.7% – Time to Sell?
03:31am, Thursday, 19'th Feb 2026
Shares of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) traded down 14.7% during trading on Wednesday. The stock traded as low as $0.8531 and last traded at $0.8531. 931,449 shares wer
CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
09:20am, Monday, 09'th Feb 2026
Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
08:30am, Wednesday, 21'st Jan 2026
Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense Ther
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
08:45am, Thursday, 08'th Jan 2026
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages
01:26am, Wednesday, 31'st Dec 2025
Shares of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) have earned an average rating of "Moderate Buy" from the five analysts that are covering the company, Marketbeat Ratings reports
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
09:17am, Monday, 22'nd Dec 2025
Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026 CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
07:30am, Thursday, 04'th Dec 2025
CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
09:56am, Monday, 24'th Nov 2025
CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to Host Investor Webinar on December 8, 2025
09:15am, Monday, 03'rd Nov 2025
Business, regulatory and clinical updates will be provided CAMBRIDGE, Mass. , Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) PT at $14.00
01:14am, Monday, 20'th Oct 2025
Shares of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) have received an average rating of "Moderate Buy" from the six brokerages that are presently covering the stock, MarketBeat repo
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
09:00am, Monday, 06'th Oct 2025
CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
02:30pm, Wednesday, 10'th Sep 2025
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass. , Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeu
